Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Outpatient Treatment with Anti-Coronavirus Immunoglobulin (OTAC)
2023-508105-24-00Phase 3Completed
- Sponsor
- University of Minnesota
- Start
- Mar 2024
- Modality
- Antibody-Based Therapeutics
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Anti-COVID-19 Hyperimmune Globulin (Human) with Placebo (normal saline) (2 arms). Primary endpoint: Clinical status on ordinal scale. Started Mar 2024; status: completed.
02
Drugs
CoviGlobulin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2023-508105-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508105-24-00.